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Abstract VEGF is an endothelial cell cytokine that promotes
angiogenesis and enhances microvascular permeability. Re-
cently, it has been shown that the protein kinase Akt functions
in a key intercellular signaling pathway downstream of VEGF.
Here, we employed adenovirus-mediated gene transfer in con-
junction with the Miles assay in hairless albino guinea pigs to
assess the role of Akt signaling in vascular permeability. VEGF-
induced vascular permeability was blocked by the transduction
of a dominant negative mutant of Akt. Conversely, transduction
of a constitutively active form of Akt promoted vascular perme-
ability in a manner similar to VEGF protein administration.
This Akt-mediated increase in vascular permeability was inhib-
ited by the eNOS inhibitor L-NAME. These data show that
Akt signaling is both necessary and su⁄cient for vascular per-
meability in an in vivo model.
* 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Vascular endothelial growth factor (VEGF) is an endothe-
lial cell cytokine that promotes angiogenesis [1]. The protein
kinase Akt, also referred to as PKB, functions downstream of
VEGF to promote survival in endothelial cells [2] and mediate
NO production through the direct phosphorylation of endo-
thelial cell nitric oxide synthase (eNOS) [3]. Akt signaling is
also essential for VEGF-mediated actin reorganization and
directed endothelial cell migration toward VEGF [4], and
for VEGF-mediated di¡erentiation of endothelial cells into
tube-like structures in vitro [5]. Because Akt has a role in
diverse cellular processes that contribute to the angiogenic
process, the status of Akt signaling within endothelial cells
may function as an important modulator of blood vessel
growth [5,6].
VEGF was ¢rst described as vascular permeability factor
(VPF), a tumor-secreted factor that increases vascular perme-
ability in guinea pig skin [7]. This property of VEGF is of
signi¢cance because angiogenesis is accompanied by an in-
crease in vascular permeability and may be required for vessel
sprouting [8^10]. Moreover, this property of VEGF may con-
tribute to tissue edema [11]. Although there is evidence to
suggest that VEGF-mediated NO production is important
for vascular permeability [11^16], this process is associated
with endothelial cell fenestration [17^19]. The signaling mech-
anisms that regulate this process are largely unknown. One
exception is the in vitro study performed by Lal et al. [20],
where it was shown that VEGF-stimulated FITC-dextran £ux
across an endothelial cell monolayer was blocked by chemical
inhibitors of MAP kinase and phosphatidylinositol 3-kinase
(PI 3-kinase). Because Akt is one of many downstream e¡ec-
tors for PI 3-kinase, we reasoned that this signaling molecule
might be involved in vascular permeability. Therefore, we in-
vestigated the role of Akt signaling in vascular permeability
using molecular modulations of this protein kinase. For this
purpose, the Miles assay of vascular permeability in guinea
pig skin was modi¢ed to accommodate adenovirus-mediated
transfer. Next we evaluated the activities of constitutively ac-
tive and dominant negative Akt1 gene constructs on vascular
permeability in this system.
2. Materials and methods
Female, hairless albino guinea pigs that are euthymic and immuno-
competent (weight: 300 to 500 g, n=30; Charles River Laboratories)
were used for these assays. Animals were lightly anesthetized with
ketamine (10 mg/kg) and xylazine (50 mg/kg). A solution of Evans
blue dye (Sigma; 0.5% in saline) was ¢ltered through a 0.2-Wm micro-
pore ¢lter (Corning) before use. The animals were given 0.5 to 1.0 ml
of 0.5% Evans blue dye through the heart, and hyperpermeable der-
mal sites (1^3 mm) were assessed based upon the intensity of the blue
bleb. Adenoviral constructs were injected intradermally in volumes of
0.1 ml 24 h before the injection of Evans blue dye. Adenoviral con-
structs encoding myristoylated, constitutively active Akt (myrAkt),
dominant negative Akt (dnAkt) and L-galactosidase (Lgal) were de-
scribed previously [2]. Viral titer was determined by plaque assays on
293 cells and is expressed as plaque forming units (PFU) per ml.
VEGF protein (RpD Systems), histamine (Sigma) and platelet acti-
vating factor (PAF, Sigma) in 0.1 ml were injected 30 min after the
injection of Evans blue dye. The NW-nitro-L-arginine methyl ester
(L-NAME) or D-NAME (20 mg/kg) were administrated through
the femoral vein immediately before the injection of Evans blue dye.
All protocols were approved by the Institutional Animal Care and
Use Committee.
3. Results
3.1. Constitutive Akt signaling promotes vascular permeability
Adenoviral constructs encoding myristoylated Akt (Adeno-
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myrAkt) or the control protein L-galactosidase (Adeno-Lgal)
were injected intradermally in the backs of hairless guinea pigs
24 h prior to the injection of Evans blue dye in the heart.
Enhanced permeability was observed at the highest dose of
Adeno-myrAkt (108 PFU), but not at lower doses (105-107
PFU). This dose^response relationship was highly reproduci-
ble and three representative experiments are shown in Fig. 1A.
In contrast, the control vector Adeno-Lgal did not shown any
evidence of enhanced vascular permeability at any dose tested
(n=4, representative data is shown in Fig. 1B).
Administration of VEGF protein (16^128 ng) 30 min after
the administration of Evans blue dye produced notable bluing
at the center of the bleb at all doses tested (Fig. 1C), similar to
previously reported data [9]. The other positive controls, his-
tamine and PAF also induced notable bluing (Fig. 1D,E).
Repeated intradermal injection of the vehicle control (saline)
did not produce vascular permeability (not shown).
3.2. Akt signaling is essential for VEGF/VPF-induced vascular
permeability
To assess whether Akt signaling is essential for VEGF-in-
duced vascular permeability, a replication-defective adenovi-
rus encoding dominant negative Akt (Adeno-dnAkt, 108
PFU) was injected intradermally 24 h prior to the injection
of Evans blue dye in the heart and the delivery of VEGF
protein to the adenovirus injection site. Pretreatment with
Adeno-dnAkt abolished VEGF-induced vascular permeability
at all doses of VEGF examined (Fig. 2A). In contrast, pre-
treatment with Adeno-dnAkt had no e¡ect on PAF-induced
vascular permeability (Fig. 2B).
3.3. Role of NO in Akt-induced vascular permeability
The NO synthase inhibitor, L-NAME (20 mg/kg), was in-
jected through the femoral vein immediately before adminis-
tration of Evans blue dye in the heart to investigate the role of
NO in Akt-mediated vascular permeability. Administration of
L-NAME eliminated vascular permeability in response to
VEGF (Fig. 3A), consistent with previous observations in
this model [9]. Administration of L-NAME also inhibited
Akt-induced vascular permeability (Fig. 3B). In contrast,
treatment with L-NAME did not alter vascular permeabil-
ity induced by PAF (data not shown). The stereoisomer
D-NAME (20 mg/kg), which does not inhibit endothelial NO
synthesis, also failed to inhibit Akt-induced vascular perme-
ability (Fig. 3B), suggesting that the Akt-mediated increase in
permeability is dependent on local NO production by eNOS.
4. Discussion
The present study demonstrates for the ¢rst time that Akt
functions as a mediator of VEGF-induced vascular permeabil-
ity in vivo. A key ¢nding was that the VEGF-induced vascu-
lar permeability in the Miles assay was e¡ectively blocked
when tissue was transduced with a dominant negative form
of Akt1. Since VEGF receptors are largely con¢ned to the
endothelial cell surface, it is reasonable to hypothesize that
dominant negative Akt interferes with functions in the endo-
thelium that are essential for vascular permeability. Presum-
Fig. 1. Constitutive activation of Akt signaling is su⁄cient for vas-
cular permeability. Representative photographs of guinea pig skin
patches after Evans blue dye injection in the heart. Intradermal in-
jections of Adeno-myrAkt (a) or Adeno-Lgal (b) were performed
24 h prior to Evans blue dye administration. Intradermal injections
of VEGF (c), histamine (d) or platelet activating factor (PAF) (e)
were performed 30 min after the administration of Evans blue dye.
a: Three examples of the dose e¡ect of Adeno-myrAkt (1U105 to
1U108 PFU) on vascular permeability are shown. Adeno-Lgal
(1U105 to 1U108 PFU) was used as negative control (b), and
VEGF protein (16, 32, 64, 128 ng) (c), histamine (1, 10, 100, 1000
nm) (d), and PAF (0.1, 1, 10, 100 Wm) (e) were used as positive
controls of vascular permeability.
Fig. 2. Akt signaling is essential for VEGF- but not PAF-induced
vascular permeability. a: Representative photographs of guinea pig
skin patches after Evans blue dye injection in the heart and subder-
mal injection of the indicated amount of VEGF protein in the pres-
ence or absence of Adeno-dnAkt (1U108 PFU). VEGF was injected
30 min after and Adeno-dnAkt was injected 24 h prior to Evans
blue dye administration. b: Platelet activating factor (PAF) was also
tested at the indicated amounts in skin patches that were previously
infected with Adeno-dnAkt (1U108 PFU).
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ably, Akt-mediated phosphorylation of eNOS in response to
VEGF stimulation [3] plays an important role in permeability
through its ability to modulate vasodilation and intraluminal
surface area [21]. In support of this hypothesis, Fukumura et
al. [16] reported that targeted disruption of eNOS, a down-
stream target of Akt, impaired VEGF-induced vascular per-
meability. In contrast, disruption of inducible NOS, which is
not a substrate of Akt, had no e¡ect on permeability. Also
consistent with this hypothesis is the current observation that
dominant negative Akt had no e¡ect on PAF-induced perme-
ability, which operates through an eNOS-independent mech-
anism.
A secondary ¢nding of this study is that transduction with
constitutively active Akt was su⁄cient to induce vascular per-
meability. Constitutively active Akt could be functioning
through the direct activation of the microvascular endothe-
lium. Alternatively, because adenovirus is an amphitrophic
vector, it is likely that this treatment also promotes Akt-medi-
ated VEGF synthesis in ¢broblasts and vascular smooth
muscle at the injection site [22]. The localized production of
VEGF would, in turn, lead to an activation of the Akt^eNOS
regulatory axis in the vascular endothelium. In this regard,
vascular permeability induced by constitutively active Akt
was blocked by L-NAME, indicating that eNOS activation
is an essential mediator of this e¡ect.
It is becoming increasingly clear that Akt signaling is essen-
tial for many of the endothelial cell responses to VEGF. In
addition to eNOS regulation, Akt controls both VEGF- and
matrix attachment-mediated signaling pathways that promote
endothelial cell survival [2], and Akt signaling is essential for
directed endothelial cell migration toward VEGF [4]. Since
enhanced vascular permeability is a feature of sprout forma-
tion, the data presented here provide further support for the
hypothesis that Akt signaling with the endothelium is an im-
portant regulator of blood vessel growth. Consistent with this
hypothesis are the observations that Akt signaling is necessary
for endothelial cell di¡erentiation to vascular structures in
vitro and reports that enhanced PI 3-kinase/Akt signaling
can promote blood vessel growth in a number of animal mod-
els [5,22,23]. Collectively, these ¢ndings reinforce the notion
that pharmacological modulation of Akt signaling could have
utility for pro- or anti-angiogenic therapies in patient popula-
tions.
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Fig. 3. The nitric oxide synthase inhibitor L-NAME blocks Akt-
mediated vascular permeability. a: Representative photographs of
guinea pig skin after Evans blue dye administration. Skin patches
received intradermal injections of VEGF 30 min after Evans blue
dye administration. Where indicated, L-NAME was administered in-
travenously immediately prior to Evans blue injection in the heart.
b: Representative photographs of blebs following the injection of
the indicated amounts of Adeno-myrAkt in animals that received
systemic injections of L-NAME or D-NAME (20 mg/kg).
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